Tirzepatide (Mounjaro / Zepbound / 穆桂諾) Tirzepatide

MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. WARNING: RISK OF THYROID C-CELL TUMORS — Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell …

Mounjaro received a marketing authorisation valid throughout the EU on 15 September 2022. The active substance in Mounjaro, tirzepatide, acts in the same way as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Mounjaro is a prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct…

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index (BMI) of at least 35 kg/m2 and at least 1 weight-related comorbidity. If less than 5% of the initial weight has been lost after 6 months on the highest tolerated dose, decide whether to continue tre…

猛健樂注射劑15毫克/0.5毫升 (MOUNJARO Injection 15mg/0.5mL)；許可證字號：衛部藥輸字第028468號；限由醫師使用；適應症：(1) 作為飲食及運動療法之外的輔助治療，用於改善第二型糖尿病成人病人之血糖控制；(2) 作為飲食及運動療法之外的輔助治療，用於體重控制（肥胖或過重）；申請商：台灣禮來股份有限公司；發證日期：112-07-19

Tirzepatide (GLP-1/GIP dual receptor agonist) used as glucose lowering therapy for adults with type 2 diabetes mellitus with established cardiovascular disease or chronic kidney disease and obesity. High prices of medicines like semaglutide and tirzepatide are limiting access to these medicines.

依據衛福部藥事法規定，Mounjaro 猛健樂為處方藥物，不得透過網路、電商平台或非合法通路自行購買。使用前應由專業醫師進行完整的身體評估、代謝狀況分析及健康風險判斷後，才可開立處方並合法使用。猛健樂於2025年6月30日由衛福部正式核准增列體重控制適應症，屬自費項目，健保不給付。

猛健樂注射劑15毫克/0.5毫升 MOUNJARO Injection 15 mg/0.5 mL 衛部藥輸字第028468號 限由醫師使用

去年體檢數字不是很滿意,GPT超標(6X),有脂肪肝現象...GPT從6X -> 4X (打猛建樂兩個月左右量的)。推文補充：我打一個月脂肪肝就沒了，肝指數從60幾跑到20幾，第三個月InBody內臟脂肪指數從8跑到4